George Mutter

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint The spectrum of endometrial pathology induced by progesterone receptor modulators
    George L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Mod Pathol 21:591-8. 2008
  2. pmc Squamous morules are functionally inert elements of premalignant endometrial neoplasia
    Ming Chieh Lin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 22:167-74. 2009
  3. ncbi request reprint Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group
    G L Mutter
    Harvard Medical School, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Gynecol Oncol 76:287-90. 2000
  4. pmc Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study
    George L Mutter
    Department of Pathology, BDivision of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 39:866-74. 2008
  5. pmc Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays
    George L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    BMC Genomics 5:88. 2004
  6. ncbi request reprint Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia
    George L Mutter
    Department of Pathology at Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 26:103-14. 2007
  7. pmc Diagnosis of premalignant endometrial disease
    G L Mutter
    Department of Pathology, Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Pathol 55:326-31. 2002
  8. ncbi request reprint Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Gynecol Oncol 83:177-85. 2001
  9. ncbi request reprint Molecular identification of latent precancers in histologically normal endometrium
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, 75Francis Street, Boston, MA 02115, USA
    Cancer Res 61:4311-4. 2001
  10. ncbi request reprint Changes in endometrial PTEN expression throughout the human menstrual cycle
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 85:2334-8. 2000

Collaborators

Detail Information

Publications37

  1. ncbi request reprint The spectrum of endometrial pathology induced by progesterone receptor modulators
    George L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Mod Pathol 21:591-8. 2008
    ..The panel has designated these changes as PRM-associated endometrial changes (PAEC). Additional follow-up studies will be needed to fully define their natural history and relationship to specific agents and administration regimens...
  2. pmc Squamous morules are functionally inert elements of premalignant endometrial neoplasia
    Ming Chieh Lin
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 22:167-74. 2009
    ..Even isolated morules should be carefully followed, however, to exclude a coexisting undersampled, or occult, glandular lesion...
  3. ncbi request reprint Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group
    G L Mutter
    Harvard Medical School, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Gynecol Oncol 76:287-90. 2000
    ..Implementation of this proposal will bring diagnostic terminology into agreement with current concepts of premalignant endometrial disease and facilitate more uniform patient management...
  4. pmc Biopsy histomorphometry predicts uterine myoinvasion by endometrial carcinoma: a Gynecologic Oncology Group study
    George L Mutter
    Department of Pathology, BDivision of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Hum Pathol 39:866-74. 2008
    ....
  5. pmc Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays
    George L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    BMC Genomics 5:88. 2004
    ..frozen vs. 24 or 72 hours RNALater), and random background (duplicates). The dataset was randomly permuted to define a baseline pattern of ANOVA test statistic values against which the observed results could be interpreted...
  6. ncbi request reprint Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia
    George L Mutter
    Department of Pathology at Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 26:103-14. 2007
    ..The resolution of hormonal and premalignant subsets of traditional "endometrial hyperplasias" is possible using redefined diagnostic criteria, enabling patient therapy to be appropriately matched with the underlying disease mechanisms...
  7. pmc Diagnosis of premalignant endometrial disease
    G L Mutter
    Department of Pathology, Harvard Medical School, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Clin Pathol 55:326-31. 2002
    ..Specialised molecular and morphometric analyses have been extremely useful in redefining clinically relevant premalignant endometrial disease, but translation to improved patient care requires the informed participation of pathologists...
  8. ncbi request reprint Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Gynecol Oncol 83:177-85. 2001
    ..We used large-scale messenger RNA expression analysis to discover genes that distinguish neoplastic transformation and examine the patterns of tumor expression of those genes which are normally regulated during the menstrual cycle...
  9. ncbi request reprint Molecular identification of latent precancers in histologically normal endometrium
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, 75Francis Street, Boston, MA 02115, USA
    Cancer Res 61:4311-4. 2001
    ..Histopathology of PTEN-null glands is initially unremarkable, but with progression, they form distinctive high-density clusters. These data are consistent with a progression model in which initial mutation is not rate limiting...
  10. ncbi request reprint Changes in endometrial PTEN expression throughout the human menstrual cycle
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Clin Endocrinol Metab 85:2334-8. 2000
    ....
  11. ncbi request reprint Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Natl Cancer Inst 92:924-30. 2000
    ..Testing the hypothesis that altered PTEN function precedes the appearance of endometrial adenocarcinoma has been difficult, however, partly because of uncertainties in precancer diagnosis...
  12. pmc K-ras mutations appear in the premalignant phase of both microsatellite stable and unstable endometrial carcinogenesis
    G L Mutter
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mol Pathol 52:257-62. 1999
    ..The distribution of k-ras mutations in microsatellite stable and unstable premalignant lesions was studied to determine whether this gene is implicated in both tumorigenic pathways...
  13. ncbi request reprint Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling
    Bradley J Quade
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Chromosomes Cancer 40:97-108. 2004
    ..These genes define a tumor signature for uterine smooth muscle neoplasia, and they suggest that the molecular pathways in leiomyoma and leiomyosarcoma are distinct...
  14. ncbi request reprint Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator
    Olga B Ioffe
    Department of Pathology, University of Maryland, Baltimore, MD, USA
    Mod Pathol 22:450-9. 2009
    ..Knowledge of the constellation of endometrial changes associated with this agent and other progesterone receptor modulators, including cystic architecture and mixed non-physiologic epithelial changes will prevent misdiagnosis...
  15. ncbi request reprint Molecular and pathologic aspects of endometrial carcinogenesis
    Jonathan L Hecht
    Department of Pathology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02215, USA
    J Clin Oncol 24:4783-91. 2006
    ..This article reviews the genetic aspects of endometrial carcinogenesis and progression. We will define the precursor lesion of type I endometrioid cancer and the role of genetics and estrogen in its progression...
  16. pmc Prediction of endometrial carcinoma by subjective endometrial intraepithelial neoplasia diagnosis
    Jonathan L Hecht
    Department of Pathology, Beth Israel Hospital, Boston, MA 02115, USA
    Mod Pathol 18:324-30. 2005
    ....
  17. doi request reprint Histologic and immunohistochemical decision-making in endometrial adenocarcinoma
    Lesley Lomo
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 21:937-42. 2008
    ..Because p53 is an important marker for endometrial adenocarcinoma outcome, and cannot be predicted in advance in indeterminate cases, p53 immunostaining should be employed in cases with observer disagreement in a binary system...
  18. pmc Evidence for a latent precursor (p53 signature) that may precede serous endometrial intraepithelial carcinoma
    Elke A Jarboe
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Mod Pathol 22:345-50. 2009
    ..The significance of p53 signatures in benign conditions (polyps) remains to be determined. The role of the p53 signature in early serous neoplasia is discussed...
  19. ncbi request reprint Estradiol-induced hyperplasia in endometrial biopsies from women on hormone replacement therapy
    Thomas C Wright
    Department of Pathology, Columbia University Presbiterian Medical Center, New York, New York 10032, USA
    Am J Surg Pathol 26:1269-75. 2002
  20. ncbi request reprint Hertig and beyond: a systematic and practical approach to the endometrial biopsy
    Christopher P Crum
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Adv Anat Pathol 10:301-18. 2003
    ..Algorithms for the laboratory management of cyclic changes, dysfunctional bleeding, and mixed-pattern endometria are provided, as are pitfalls in interpretation and exclusion of neoplasia...
  21. ncbi request reprint Involution of PTEN-null endometrial glands with progestin therapy
    Wenxin Zheng
    Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
    Gynecol Oncol 92:1008-13. 2004
    ....
  22. pmc Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer
    Nicolas M Monte
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Cancer Res 70:6225-32. 2010
    ..Loss of function of both genes in an overlapping distribution characterizes the clinical emergence of a premalignant lesion which is carried forward to carcinoma...
  23. pmc Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube
    Eleanor Y Chen
    Division of Women s and Perinatal Pathology, Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    J Pathol 222:110-6. 2010
    ....
  24. doi request reprint Coexisting intraepithelial serous carcinomas of the endometrium and fallopian tube: frequency and potential significance
    Elke A Jarboe
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Int J Gynecol Pathol 28:308-15. 2009
    ....
  25. ncbi request reprint Biomarkers in diagnostic obstetric and gynecologic pathology: a review
    Marisa R Nucci
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, Massachussetts 02115, USA
    Adv Anat Pathol 10:55-68. 2003
    ....
  26. ncbi request reprint Identification of differentially expressed genes in high-density oligonucleotide arrays accounting for the quantification limits of the technology
    Mahlet G Tadesse
    Department of Statistics, Texas A and M University, College Station, Texas, USA
    Biometrics 59:542-54. 2003
    ..We examine the performance of our proposed method on simulated data, then present a detailed case study of an endometrial cancer dataset...
  27. pmc Risk of subsequent endometrial carcinoma associated with endometrial intraepithelial neoplasia classification of endometrial biopsies
    James V Lacey
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland 20852 7234, USA
    Cancer 113:2073-81. 2008
    ..The authors estimated progression risk associated with EIN among endometrial biopsies in a nested case-control study of EH progression...
  28. pmc PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma
    James V Lacey
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA
    Cancer Res 68:6014-20. 2008
    ..Loss of PTEN expression in endometrial biopsies was neither associated with nor a sensitive and specific marker of subsequent progression to endometrial carcinoma...
  29. pmc Regression of latent endometrial precancers by progestin infiltrated intrauterine device
    Anne ├śrbo
    Department of Pathology, University of Tromso, Tromso, Norway
    Cancer Res 66:5613-7. 2006
    ....
  30. ncbi request reprint Combined total genome loss of heterozygosity scan of breast cancer stroma and epithelium reveals multiplicity of stromal targets
    Koichi Fukino
    Clinical Cancer Genetics Program, Division of Human Cancer Genetics, Department of Molecular Virology, Immunology, and Medical Genetics, School of Public Health, The Ohio State University, Columbus, Ohio, USA
    Cancer Res 64:7231-6. 2004
    ..Genetic alterations in stroma did not mimic those in epithelium, but they could play a different and parallel role in carcinogenesis and tumor progression, probably by modifying some features specific to breast cancer...
  31. pmc The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system
    Jan P Baak
    Department of Pathology, Stavanger University Hospital, Stavanger, Norway
    Cancer 103:2304-12. 2005
    ....
  32. ncbi request reprint Lack of PTEN expression in endometrial intraepithelial neoplasia is correlated with cancer progression
    Jan Pieter Albert Baak
    Department of Pathology, Stavanger University Hospital, Norway
    Hum Pathol 36:555-61. 2005
    ..Unless endometrial hyperplasias are stratified by histological morphometric D-Score, PTEN has a low positive predictive value...
  33. ncbi request reprint Breast-cancer stromal cells with TP53 mutations and nodal metastases
    Attila Patocs
    Genomic Medicine Institute, Cleveland Clinic Foundation, Cleveland 44195, USA
    N Engl J Med 357:2543-51. 2007
    ..We hypothesized that mutational inactivation of the tumor-suppressor gene TP53 and genomic alterations in stromal cells of a tumor's microenvironment contribute to the clinical outcome...
  34. ncbi request reprint Genomic instability within tumor stroma and clinicopathological characteristics of sporadic primary invasive breast carcinoma
    Koichi Fukino
    Genomic Medicine Institute, Lerner Research Institute and Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    JAMA 297:2103-11. 2007
    ..That genomic alterations occur in both the epithelium and stroma of sporadic breast cancers has been documented by several groups. However, whether these microenvironmental alterations relate to clinicopathological features is unknown...
  35. pmc p63 Coordinates anogenital modeling and epithelial cell differentiation in the developing female urogenital tract
    Tan A Ince
    Department of Pathology, Division of Women s and Perinatal Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Pathol 161:1111-7. 2002
    ..The second is necessary for the generation of multipotential reserve cells in the cervix and may be operative in other epithelial stromal interactions integral to the emergence of uterine basal cells later in life...
  36. ncbi request reprint Precancer: a conceptual working definition -- results of a Consensus Conference
    Jules J Berman
    Cancer Diagnosis Program, National Cancer Institute, NIH, Bethesda, MD, USA
    Cancer Detect Prev 30:387-94. 2006
    ..Precancers are lesions that precede the appearance of invasive cancers. The successful prevention or treatment of precancers has the potential to eliminate deaths due to cancer...
  37. pmc Total-genome analysis of BRCA1/2-related invasive carcinomas of the breast identifies tumor stroma as potential landscaper for neoplastic initiation
    Frank Weber
    Genomic Medicine Institute, Cleveland Clinic Lerner Research Institute, Cleveland, OH 44195, USA
    Am J Hum Genet 78:961-72. 2006
    ....

Research Grants10

  1. Biomarkers and Chemoprevention of Endometrial Cancer
    George Mutter; Fiscal Year: 2006
    ..If successful, we will be able to rapidly implement a rational and effective strategy for early detection and chemoprevention of endometrial carcinoma. ..
  2. Hormonal modulation of latent endometrial precancers
    George Mutter; Fiscal Year: 2007
    ..If our hypothesis is confirmed, this project will establish biomarker-detectable preclinical disease as a surrogate marker for risk surveillance, and a potential target for cancer preventative therapies. ..
  3. Biomarkers and Chemoprevention of Endometrial Cancer
    George Mutter; Fiscal Year: 2002
    ..If successful, we will be able to rapidly implement a rational and effective strategy for early detection and chemoprevention of endometrial carcinoma. ..
  4. Hormonal modulation of latent endometrial precancers
    George Mutter; Fiscal Year: 2006
    ..If our hypothesis is confirmed, this project will establish biomarker-detectable preclinical disease as a surrogate marker for risk surveillance, and a potential target for cancer preventative therapies. ..
  5. Biomarkers and Chemoprevention of Endometrial Cancer
    George Mutter; Fiscal Year: 2005
    ..If successful, we will be able to rapidly implement a rational and effective strategy for early detection and chemoprevention of endometrial carcinoma. ..
  6. Hormonal modulation of latent endometrial precancers
    George Mutter; Fiscal Year: 2005
    ..If our hypothesis is confirmed, this project will establish biomarker-detectable preclinical disease as a surrogate marker for risk surveillance, and a potential target for cancer preventative therapies. ..
  7. Biomarkers and Chemoprevention of Endometrial Cancer
    George Mutter; Fiscal Year: 2004
    ..If successful, we will be able to rapidly implement a rational and effective strategy for early detection and chemoprevention of endometrial carcinoma. ..
  8. Hormonal modulation of latent endometrial precancers
    George Mutter; Fiscal Year: 2004
    ..If our hypothesis is confirmed, this project will establish biomarker-detectable preclinical disease as a surrogate marker for risk surveillance, and a potential target for cancer preventative therapies. ..
  9. Biomarkers and Chemoprevention of Endometrial Cancer
    George Mutter; Fiscal Year: 2003
    ..If successful, we will be able to rapidly implement a rational and effective strategy for early detection and chemoprevention of endometrial carcinoma. ..